Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis

被引:61
作者
Graziadei, IW
Obermoser, GE
Sepp, NT
Erhart, KH
Vogel, W
机构
[1] Univ Innsbruck, Dept Internal Med, Dept Gastroenterol & Hepatol, A-6020 Innsbruck, Austria
[2] Univ Innsbruck, Dept Dermatol, A-6020 Innsbruck, Austria
[3] Dist Hosp, Bregenz, Austria
关键词
atorvastatin; lupus-like syndrome; liver failure; autoimmune hepatitis;
D O I
10.1191/0961203303lu313cr
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Atorvastatin and other members of the statin family are widely used for the treatment of hypercholesterolaemia in order to reduce the risk of atherosclerosis and cardiovascular disease. Atorvastatin-induced adverse events are mostly mild and only a few cases of lupus-like syndrome or severe acute hepatitis have been documented. In this case report we describe a patient who developed an atorvastatin-induced severe autoimmune hepatitis. In addition, this patient presented with a concomitant systemic lupus-like syndrome which has been already described for statins but not in association with severe liver disease. Although the drug was immediately withdrawn the disease persisted and even deteriorated to a fulminant disease with evidence of acute hepatic failure. The patient failed to respond to conventional immunosuppression with corticosteroids and azathioprine. Only the introduction of intense immunosuppressive therapy, as used in solid organ transplantation, led to a complete and sustained recovery of the patient. Interestingly, the patient was HLA DR3- and HLA DR4-positive, which are well-known genetic factors associated with autoimmune diseases. This case is the first report of a drug-induced lupus-like syndrome concomitant with a severe autoimmune hepatitis in a genetically predisposed patient.
引用
收藏
页码:409 / 412
页数:4
相关论文
共 16 条
[1]  
Ahmad A, 2000, Tenn Med, V93, P21
[2]   LOVASTATIN-INDUCED LUPUS-ERYTHEMATOSUS [J].
AHMAD, S .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (08) :1667-1668
[3]   Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions [J].
Aithal, GP ;
Rawlins, MD ;
Day, CP .
JOURNAL OF HEPATOLOGY, 2000, 33 (06) :949-952
[4]   International Autoimmune Hepatitis Group Report:: review of criteria for diagnosis of autoimmune hepatitis [J].
Alvarez, E ;
Berg, PA ;
Bianchi, FB ;
Bianchi, L ;
Burroughs, AK ;
Cancado, EL ;
Chapman, RW ;
Cooksley, WGE ;
Czaja, AJ ;
Desmet, VJ ;
Donaldson, RT ;
Eddleston, ALWF ;
Fainboim, L ;
Heathcote, J ;
Homberg, JC ;
Hoofnagle, JH ;
Kakumu, S ;
Krawitt, EL ;
Mackay, IR ;
MacSween, RNM ;
Maddrey, WC ;
Manns, MP ;
McFarlane, IG ;
zum Büschenfelde, KHM ;
Mieli-Vergani, G ;
Nakanuma, Y ;
Nishioka, M ;
Penner, E ;
Porta, G ;
Portmann, BC ;
Reed, WD ;
Rodes, J ;
Schalm, SW ;
Scheuer, PJ ;
Schrumpf, E ;
Seki, T ;
Toda, G ;
Tsuji, T ;
Tygstrup, N ;
Vergani, D ;
Zeniya, M .
JOURNAL OF HEPATOLOGY, 1999, 31 (05) :929-938
[5]   LUPUS-LIKE SYNDROME ASSOCIATED WITH SIMVASTATIN [J].
BANNWARTH, B ;
MIREMONT, G ;
PAPAPIETRO, PM .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (05) :1093-1093
[6]  
BENICHOU C, 1990, J HEPATOL, V11, P272
[7]   An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor [J].
Black, DM ;
Bakker-Arkema, RG ;
Nawrocki, JW .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (06) :577-584
[8]   Drug therapy in the management of type 1 autoimmune hepatitis [J].
Czaja, AJ .
DRUGS, 1999, 57 (01) :49-68
[9]   FEATURES REFLECTIVE OF EARLY PROGNOSIS IN CORTICOSTEROID-TREATED SEVERE AUTOIMMUNE CHRONIC ACTIVE HEPATITIS [J].
CZAJA, AJ ;
RAKELA, J ;
LUDWIG, J .
GASTROENTEROLOGY, 1988, 95 (02) :448-453
[10]  
Gough A, 1996, BRIT MED J, V312, P169